Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Healthtrust
Accenture
Citi
AstraZeneca
Fish and Richardson
Covington
Daiichi Sankyo
Dow
Cantor Fitzgerald

Generated: August 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Inventor(s): Kung; Hank F. (Wynnewood, PA), Kung; Mei-Ping (Wynnewood, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:12/186,072
Patent Claims: 1. A compound of the formula: ##STR00039## wherein, R.sup.a and R.sup.b are independently hydrogen or methyl, and Z is --F or --.sup.18F.

2. The compound of claim 1 of the formula: ##STR00040##

3. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

4. A composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier or diluent.

5. A method of imaging amyloid deposits in a mammal, comprising: introducing into the mammal a detectable quantity of a compound of claim 1; allowing sufficient time for the compound to be associated with one or more amyloid deposits; and detecting the compound associated with one or more amyloid deposits.

6. A method of imaging amyloid deposits in a mammal, comprising: introducing into the mammal a detectable quantity of a composition of claim 3; allowing sufficient time for the compound to be associated with one or more amyloid deposits; and detecting the compound associated with one or more amyloid deposits.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
McKesson
Queensland Health
Johnson and Johnson
Cantor Fitzgerald
Healthtrust
McKinsey
Deloitte
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot